Interestingly, BCL9 acts as an enhancer of β-catenin signaling in colon cancer and is considered to be an oncogene [42], and the WT form of BCL9 seems to slightly suppress the canonical pathway. This evidence concerns the gene BCL9 and malignant colon neoplasm.